Skip to main content

ContextVision AB (publ) (0L8Z.L)

London Stock Exchange Technology Software - ApplicationView data quality →
45.0Fair

ValueMarkers Composite Index

Top 13%#38,866 of 44,722
Undervalued

87% below intrinsic value ($3)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
5.00
High Risk
Altman
6.98
Safe
DCF Value
$3
Undervalued
ROIC
0.5%
Low
P/E
369.3
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

ContextVision AB (publ) (0L8Z.L) — VMCI valuation read

ContextVision AB (publ) sits at VMCI 45/100, with the Technology sector median at 50. That 5-point spread is the first thing to note on 0L8Z.L: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 0L8Z.L are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 0L8Z.L: 0L8Z.L trades at 16.0x earnings, 11% below the Technology median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Technology median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of -0.5x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

0L8Z.L rose 2.7% over the trailing 7 days, with a -6.7% read on a 30-day basis.

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; and GOPiCE, a technology for volumetric image enhancement in real-time. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.

CEO: Gerald Potzsch35 employeesSEwww.contextvision.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.